Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer
Ningning Cheng(Tongji University), Caicun Zhou(Tongji University), Qi Wang(Union Hospital), Xuefei Li(Chengdu University of Traditional Chinese Medicine), Jiayu Li(Tongji University), Chao Zhao(Tongji University), Weijing Cai(Icahn School of Medicine at Mount Sinai), Mingchuan Zhao(Tongji University), Shengxiang Ren(Tongji University), Xiaoxia Chen(Shanghai Pulmonary Hospital), Yishi Zhang(Tongji University)
Cited by 82
Related Papers
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells
|Cell Reports|2022|465
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311